The FDA has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose programmed death ligand-1 (PD-L1) score is ≥1.
The additional indication is based on results from BeiGene’s RATIONALE-306 (ClinicalTrials.gov. Identifier: NCT03783442), a randomized, placebo-controlled, double-blind, global phase 3 study to evaluate the efficacy
MARCH 4, 2025